Compare iShares MSCI Singapore ETF (EWS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Nuwellis Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.51 (market cap $1.49B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: iShares MSCI Singapore ETF is far larger — about 677.3× Nuwellis Inc's market cap, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Nuwellis Inc for 26 Days on average.
| EWS | NUWE | |
|---|---|---|
Market Cap | $1.49B | $2.20M |
Volume | 2,142,305 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $146.65 |
52-Week Low | $26.71 | $0.68 |
Typical Hold Time | 45 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
